Loading...
Market
Regulatory approval status of the sale by end of 2024?
5
Resolution / Starting Odds
Approved without conditions • 33%
Approved with conditions • 33%
Not approved • 33%
Official announcements from regulatory bodies, Edwards Lifesciences, or Becton Dickinson
Story
Edwards Lifesciences to Sell Critical Care Unit to Becton Dickinson for $4.2 Billion in Cash
Jun 3, 2024, 12:26 PM
Edwards Lifesciences has agreed to sell its critical care products unit to Becton Dickinson for $4.2 billion in an all-cash transaction. The move is aimed at allowing Edwards Lifesciences to focus more on its heart devices business. Becton Dickinson, also known as BD, plans to expand its portfolio of smart medical monitoring and patient monitoring products through this acquisition. The deal was announced on Monday, June 3, 2024, and has positively impacted the stock prices of both companies, with BDX up 2.2% and EW up 3.6% in pre-market trading.
View original story
Similar markets
Approved • 50%
Not Approved • 50%
Yes • 50%
No • 50%
Approved without conditions • 33%
Approved with conditions • 34%
Rejected • 33%
Full Market Clearance • 33%
Conditional Market Clearance • 33%
No Clearance • 34%
Approval without conditions • 25%
Approval with conditions • 25%
Extended review • 25%
Rejection of the deal • 25%
Federal clearance granted • 33%
Federal clearance denied • 33%
Further review required • 34%
Approved in EU • 25%
Approved in Asia • 25%
Approved in LATAM • 25%
Not approved in other regions • 25%
Approved in USA • 25%
Approved in EU • 25%
Approved in both USA and EU • 25%
Not approved in either • 25%